LDLR and hepatocellular carcinoma: Extracts were tested in two key targets players, LDL receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9), in two human hepatoma cell lines (Huh7 and HepG2), to investigate the in vitro ability to modulate cholesterol metabolism [15,16].